Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
RECIST
Description:
RECIST is a standardized set of criteria for assessing changes in solid tumors to evaluate cancer treatment response.
Related topics:
Medical Imaging Techniques and Applications (14%),
Hepatocellular Carcinoma Treatment and Prognosis (10%)
Wikidata ID:
wiki/Q2145898
OpenAlex ID:
keywords/recist
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000
·
Patrick Therasse
, Susan G. Arbuck
, et al.
·
JNCI Journal of the National Cancer Institute
·
15,773
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009
·
Richard L. Wahl
, Heather Jacene
, et al.
·
Journal of Nuclear Medicine
·
3,880
PDF
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008
·
Howard I. Scher
, Susan Halabi
, et al.
·
Journal of Clinical Oncology
·
2,273
PDF
Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria
2007
·
Haesun Choi
, Chuslip Charnsangavej
, et al.
·
Journal of Clinical Oncology
·
1,536
PDF
We Should Desist Using RECIST, at Least in GIST
2007
·
Robert S. Benjamin
, Haesun Choi
, et al.
·
Journal of Clinical Oncology
·
559
Novel patterns of response under immunotherapy
2019
·
E. Borcoman
, Y. Kanjanapan
, et al.
·
Annals of Oncology
·
546
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
2013
·
Mizuki Nishino
, Anita Giobbie-Hurder
, et al.
·
Clinical Cancer Research
·
528
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
2003
·
S. Stroobants
, J. Goeminne
, et al.
·
European Journal of Cancer
·
524
Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
2009
·
Yun Shin Chun
, Jean-Nicolas Vauthey
, et al.
·
JAMA
·
501
Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response
2003
·
Jeremy J. Erasmus
, Gregory W. Gladish
, et al.
·
Journal of Clinical Oncology
·
482
CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET Findings
2004
·
Haesun Choi
, Chuslip Charnsangavej
, et al.
·
American Journal of Roentgenology
·
462
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
2012
·
Elizabeth A. Punnoose
, Siminder Atwal
, et al.
·
Clinical Cancer Research
·
428
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?
2008
·
Alejandro Forner
, Carmen Ayuso
, et al.
·
Cancer
·
427
PDF
RECIST revisited: A review of validation studies on tumour assessment
2006
·
P. Therasse
, E.A. Eisenhauer
, et al.
·
European Journal of Cancer
·
426
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
2017
·
A. Younes
, P. Hilden
, et al.
·
Annals of Oncology
·
388
PDF
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
2017
·
Julie R. Park
, Rochelle Bagatell
, et al.
·
Journal of Clinical Oncology
·
385
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
2004
·
Gordon J. S. Rustin
, Michael Quinn
, et al.
·
JNCI Journal of the National Cancer Institute
·
380
PDF
Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker
2011
·
Vicky Goh
, Balaji Ganeshan
, et al.
·
Radiology
·
371
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
2004
·
Gerald Antoch
, Jörg Kanja
, et al.
·
PubMed
·
312
Measures of Response: RECIST, WHO, and New Alternatives
2006
·
C. Carl Jaffe
·
Journal of Clinical Oncology
·
309
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma
2018
·
Ning Lyu
, Yanan Kong
, et al.
·
Journal of Hepatology
·
296
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria
2013
·
Temel Tirkes
, Margaret A. Hollar
, et al.
·
Radiographics
·
288
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times
2008
·
Anne Laure Giraudet
, Abir Al Ghulzan
, et al.
·
European Journal of Endocrinology
·
277
Patterns of Response and Progression to Immunotherapy
2018
·
Edith Borcoman
, Amara Nandikolla
, et al.
·
American Society of Clinical Oncology Educational Book
·
271
Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice
2019
·
Ugonma N Chukwueke
, Patrick Y Wen
·
CNS Oncology
·
264
PDF
Show more works
View as search
Works count:
1,794
Citation count:
61,700
Year
Topic
Type